The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.
Pierre Laurent-Puig
Consultant or Advisory Role - IntegraGen; Merck Serono; Sanofi
John A. Bridgewater
Consultant or Advisory Role - AstraZeneca; Merck; Roche; Sanofi
John Neil Primrose
Consultant or Advisory Role - Bayer; Merck; Roche; Sanofi
Sian Alexandra Pugh
No relevant relationships to disclose
Gareth Thomas
No relevant relationships to disclose
Karwan Moutasim
No relevant relationships to disclose
Francis Rousseau
Employment or Leadership Position - IntegraGen
Karine Fontaine
Employment or Leadership Position - IntegraGen
Celine Vazart
Employment or Leadership Position - IntegraGen
Virginie Decaulne
Employment or Leadership Position - IntegraGen
Anne Leclair
Employment or Leadership Position - IntegraGen
Berengere Genin
Employment or Leadership Position - IntegraGen
Sandrine Imbeaud
Consultant or Advisory Role - IntegraGen
Francois Liebaert
Employment or Leadership Position - IntegraGen
Raphaƫle ThiƩbaut
Employment or Leadership Position - IntegraGen